What is the recommended dose of Adderall (amphetamine and dextroamphetamine) for a patient with hypersomnia?

Adderall Dosing for Hypersomnia

For hypersomnia, dextroamphetamine (the active component of Adderall) should be started at 5-10 mg orally upon awakening, with titration in 5-10 mg increments weekly until optimal response is achieved, typically reaching a total daily dose range of 5-60 mg divided into 1-2 doses. 1

Initial Dosing Strategy

• Start with 5-10 mg orally upon awakening for adults with narcolepsy or other central hypersomnias, as this represents the FDA-approved starting dose for dextroamphetamine in hypersomnia 1
• The American Academy of Sleep Medicine conditionally recommends dextroamphetamine for treatment of narcolepsy in adults, supporting its use in central hypersomnolence disorders 2
• For patients 12 years and older with narcolepsy, the FDA label specifies starting with 10 mg daily 1

Titration Protocol

• Increase the dose by 5-10 mg at weekly intervals until optimal symptom control is achieved 1
• The usual effective dose range is 5-60 mg per day in divided doses, depending on individual patient response 1
• If a second dose is needed, administer it 4-6 hours after the first dose, but avoid late evening doses due to insomnia risk 1

Practical Dosing Considerations

• Give the first dose immediately upon awakening to maximize daytime alertness and minimize sleep interference 1
• Additional doses (1 or 2) should be spaced at 4-6 hour intervals 1
• The last dose should be given no later than 2:00 PM to avoid nighttime sleep disruption 2, 3
• If bothersome adverse reactions appear (such as insomnia or anorexia), reduce the dosage 1

Comparison to Alternative Stimulants

While dextroamphetamine is effective, modafinil represents the strongest first-line recommendation for central hypersomnolence disorders based on current guidelines:

• The American Academy of Sleep Medicine provides a STRONG recommendation for modafinil in both narcolepsy and idiopathic hypersomnia 2
• Dextroamphetamine receives only a CONDITIONAL recommendation for narcolepsy, indicating weaker evidence 2
• Methylphenidate is also conditionally recommended and may be preferred in patients with insomnia concerns, as it causes less sleep disruption than amphetamines 2, 4

Clinical Context and Monitoring

• Dextroamphetamine should be considered second-line therapy after modafinil or when modafinil proves inadequate 2, 5, 6
• In clinical practice, methylphenidate is often chosen more frequently than modafinil as final monotherapy despite being less commonly used initially, with 95% response rates versus 88% for modafinil 4
• For refractory daytime sedation in palliative care settings, methylphenidate or dextroamphetamine can be started at 2.5-5 mg orally with breakfast, with a second dose at lunch if needed 2

Common Pitfalls to Avoid

• Do not dose amphetamines in the late afternoon or evening, as this will cause insomnia and worsen overall sleep architecture 1
• Do not start with maximum doses—titrate gradually to minimize adverse effects while achieving symptom control 1
• Do not use amphetamines as first-line therapy when modafinil or other wake-promoting agents with stronger evidence are available 2
• Monitor for cardiovascular effects, appetite suppression, and psychiatric symptoms during titration 2